KRX 168
Alternative Names: KRX-168Latest Information Update: 21 Dec 2018
At a glance
- Originator Keryx Biopharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Post-surgical adhesions
Most Recent Events
- 13 Dec 2018 Akebia Therapeutics merged with Keryx Pharmaceuticals to form Akebia Therapeutics
- 03 Dec 2006 Discontinued - Preclinical for Post-surgical adhesions in Israel
- 05 Oct 2000 New profile